Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02732210 · ClinicalTrials.gov registry record
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
A clinical trial, sponsored by Amgen.
- Completed
- Registry status
- 935
- Enrollment target
NCT02732210: Completed study, sponsored by Amgen.
NCT02732210 is a clinical trial that has completed, run by Amgen. The registered enrollment target is 935 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02732210 has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 935 participants
- Enrollment target
Study Summary
The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
Primary Outcome
A participant was considered persistent with Prolia® at 12 months if they received at least 2 Prolia® injections no more than 6 months plus 8 weeks (239 days) apart.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 935 participants |
| Start Date | 2011-07-06 |
| Est. Completion | 2014-04-14 |
What the finished NCT02732210 record still lists
NCT02732210 is an observational study that tracks outcomes without assigning an intervention. The registered 935 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02732210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02732210 about?
NCT02732210 is a clinical study titled "Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis". The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
What is the current status of trial NCT02732210?
This trial is currently completed. The enrollment target is 935 participants. The study started on 2011-07-06. Estimated completion is 2014-04-14.
Who is sponsoring clinical trial NCT02732210?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519007 · 936 participants · NA
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- NCT06855277 · 940 participants · Phase 3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI